We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current MGCLD market cap is 1.77B. The company's latest EPS is AUD -0.0060 and P/E is -63.33.
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 988k | 2.75M | 3.85M | 4.74M | 4.16M |
| Operating Income | -10.72M | -17M | -11.8M | -19.4M | -18.14M |
| Net Income | -8.58M | -19.36M | -15.87M | -20.35M | -20.82M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 13M | 7.93M | 24.24M | 18.56M | 9.98M |
| Total Liabilities | 2.2M | 4.84M | 10.41M | 13.38M | 18.02M |
| Total Equity | 10.8M | 3.09M | 13.83M | 5.18M | -8.03M |
| Year End June 29 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -6.35M | -9.96M | -11.99M | -12.16M | -11.99M |
| Investing | -947k | -970k | -1.49M | -1.11M | 606k |
| Financing | 27k | 10.46M | 17.05M | 9.74M | 9.73M |
| Market Cap | 1.77B |
| Price to Earnings Ratio | -63.33 |
| Price to Sales Ratio | 316.67 |
| Price to Cash Ratio | 3.8k |
| Price to Book Ratio | -163.25 |
| Dividend Yield | - |
| Shares Outstanding | 3.45B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 33.12% |
| 52 Week High | 0.5125 |
| 52 Week Low | 0.2975 |
| Spread (Intraday) | 4.65 (99.98%) |
| Company Name | MGC Pharmaceuticals Ltd (PK) |
| Address |
1202 hay street perth, western australia 6005 |
| Website | https://www.mgcpharma.com.au |
| Industry | drug & proprietary stores (5912) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
